The gene therapies for cancer treatment market size was valued at US$ 11.59 billion in 2025 and is projected to grow to 16.22 billion in 2026. Forecasts suggest it will reach approximately US$ 238.77 ...

Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...

ImmunoAct, backed by government funding, is advancing CAR-T cell therapy to make cancer treatment more accessible. Their product, NexCAR19, uses patients' immune systems to fight cancer. With support ...

In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the ...

Our results suggest that patients who are considering lentiviral vector gene therapy should continue to be educated on the risk of hematologic cancer and, if treated, monitored closely.

Through studies that were amongst the largest of their kind, we identified several genes involved in breast and/or ovarian cancer predisposition such as CHEK2, BRIP1, ATM, PALB2, RAD51C and RAD51D.

Scientists looked at multiple techniques used to measure the modified viruses deployed in some gene therapy research and treatments. One technique, known as SEC-MALS, was the most precise and accurate ...

Some gene therapy treatments use modified adeno-associated viruses (AAVs) like the one shown here to deliver therapeutic genetic material into a patient’s cells. In a finding with implications for one ...

After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona in certain patients. The FDA has updated Skysona’s indication, allowing it ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...